Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479219
Status:
COMPLETED
Last Update Posted:
2008-07-10
First Post:
2007-05-25
Brief Title:
Study Evaluating GSI-953 in Healthy Young and Alzheimers Patients
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Single Dose Study of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the pharmacodynamics PD of biomarkers amyloid beta peptide 40 and 42 Ab40 and Ab42 in CSF following single oral doses of GSI-953 an investigational drug in healthy young subjects and patients with Alzheimer Disease AD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None